Literature DB >> 12626767

Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes.

Magnus M Berglund1, Philip A Hipskind, Donald R Gehlert.   

Abstract

The three peptides pancreatic polypeptide (PP), peptide YY (PYY), and neuropeptide Y (NPY) share a similar structure known as the PP-fold. There are four known human G-protein coupled receptors for the PP-fold peptides, namely Y1, Y2, Y4, and Y5, each of them being able to bind at least two of the three endogenous ligands. All three peptides are found in the circulation acting as hormones. Although NPY is only released from neurons, PYY and PP are primarily found in endocrine cells in the gut, where they exert such effects as inhibition of gall bladder secretion, gut motility, and pancreatic secretion. However, when PYY is administered in an experimental setting to animals, cloned receptors, or tissue preparations, it can mimic the effects of NPY in essentially all studies, making it difficult to study the effects of PP-fold peptides and to delineate what receptor and peptide accounts for a particular effect. Initial studies with transgenic animals confirmed the well-established action of NPY on metabolism, food-intake, vascular systems, memory, mood, neuronal excitability, and reproduction. More recently, using transgenic techniques and novel antagonists for the Y1, Y2, and Y5 receptors, NPY has been found to be a key player in the regulation of ethanol consumption and neuronal development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626767     DOI: 10.1177/153537020322800301

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  42 in total

Review 1.  Voices from within: gut microbes and the CNS.

Authors:  Paul Forsythe; Wolfgang A Kunze
Journal:  Cell Mol Life Sci       Date:  2012-05-27       Impact factor: 9.261

2.  BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.

Authors:  Yvan Dumont; Pierrette Gaudreau; Manuela Mazzuferi; Daniel Langlois; Jean-Guy Chabot; Alain Fournier; Michele Simonato; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 3.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 5.  Gastrointestinal hormones regulating appetite.

Authors:  Owais Chaudhri; Caroline Small; Steve Bloom
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 6.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

7.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

8.  Neuropeptide Y Y5 receptor antagonism attenuates cocaine-induced effects in mice.

Authors:  Gunnar Sørensen; Morten Jensen; Pia Weikop; Ditte Dencker; Søren H Christiansen; Claus Juul Loland; Cecilie Hee Bengtsen; Jørgen Holm Petersen; Anders Fink-Jensen; Gitta Wörtwein; David P D Woldbye
Journal:  Psychopharmacology (Berl)       Date:  2012-02-25       Impact factor: 4.530

9.  Comparison of fragments comprising the first two helices of the human Y4 and the yeast Ste2p G-protein-coupled receptors.

Authors:  Xuan Shao; Chao Zou; Fred Naider; Oliver Zerbe
Journal:  Biophys J       Date:  2012-08-22       Impact factor: 4.033

10.  Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.

Authors:  Edwin K Jackson; Stanton J Kochanek; Delbert G Gillespie
Journal:  Hypertension       Date:  2012-07-16       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.